Delayed kidney transplantation after HLA-haploidentical hematopoietic cell transplantation in a young woman with myelodysplastic syndrome with renal failure

Kevin C Miller; Aric C Hall; Abraham Cohen-Bucay; Yi-Bin Chen

doi:10.1016/j.lrr.2022.100302

Delayed kidney transplantation after HLA-haploidentical hematopoietic cell transplantation in a young woman with myelodysplastic syndrome with renal failure

Leuk Res Rep. 2022 Mar 17:17:100302. doi: 10.1016/j.lrr.2022.100302. eCollection 2022.

Authors

Kevin C Miller¹, Aric C Hall², Abraham Cohen-Bucay³, Yi-Bin Chen⁴

Affiliations

¹ Department of Medicine, Massachusetts General Hospital, Boston, MA, United States.
² Division of Hematology, Medical Oncology and Palliative Care, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States.
³ Renal Division and Transplant Center, Massachusetts General Hospital, Boston, MA, United States.
⁴ Hematopoietic Cell Transplant & Cell Therapy Program, Massachusetts General Hospital, Boston, MA, United States.

Abstract

Patients with end-stage renal disease (ESRD) are often excluded from potentially curative allogeneic hematopoietic cell transplantation (alloHCT). Our institution pioneered simultaneous living donor kidney transplantation in patients undergoing alloHCT from the same donor for hematologic malignancies. Herein, we present the case of a 31-year-old woman diagnosed with myelodysplastic syndrome who developed ESRD during cytoreductive induction therapy. She achieved disease control, then successfully underwent a human leukocyte antigen (HLA)-haploidentical alloHCT while on hemodialysis. After rapidly tapering off graft-versus-host disease prophylaxis, fourteen months from her alloHCT she received a kidney transplant from her same haploidentical sibling donor, which obviated the need for further systemic immunosuppression.

Keywords: Haploidentical; Hematopoietic cell transplant; Kidney transplant; Stem cell transplant.

Publication types

Case Reports